Universidad del Desarrollo

Now showing 1 - 6 of 6

Some of the metrics are blocked by your
consent settings
Integration of T‐cell clonality screening using <scp>TRBC</scp>‐1 in lymphoma suspect samples by flow cytometry
(2023)
Felipe Castillo
;
Constanza Morales
;
Biserka Spralja
;
Joaquín Díaz‐Schmidt
;
IRURETAGOYENA BRUCE, MIRENTXU INES
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>The diagnosis of T‐cell non‐Hodgkin lymphomas (NHL) is challenging. The development of a monoclonal antibody specific for T‐cell receptor β constant region 1 (TRBC1) provides an alternative to discriminate clonal T cells. The aim of this study was to evaluate the diagnostic potential of an anti‐TRBC1 mAb for the identification of T‐NHL.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We performed a cross‐sectional diagnostic analytic study of samples tested for lymphoma. All samples sent for lymphoma screening were first evaluated using the standard Euroflow LST, to which a second additional custom‐designed T‐cell clonality assessment tube was added CD45/TRBC1/CD2/CD7/CD4/TCRγδ/CD3. Flow cytometry reports were compared with morphological and molecular tests.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Fifty‐nine patient samples were evaluated. Within the T‐cell population, cut‐off percentages in the CD4+ cells were from 29.4 to 54.6% and from 23.9 to 52.1% in CD8+ cells. Cut‐off ratios in CD4+ T cells were from 0.33 to 1.1, and in CD8+ cells between 0.22 and 1.0. Using predefined normal cut‐off values, 18 of 59 (30.5%) samples showed a restricted expression of TRBC1. A final diagnosis of a T‐NHL was confirmed clinically and/or by histopathological studies in 15 of the 18 cases (83.3%). There were no cases of T‐NHL by morphology/IHC with normal TRBC1 expression. Non‐neoplastic patient samples behaved between predefined TRBC1 cut‐off values.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Expression of TRBC1 provides a robust method for T‐cell clonality assessment, with very high sensitivity and good correlation with complementary methods. TRBC1 can be integrated into routine lymphoma screening strategies via flow cytometry.</jats:p></jats:sec>
Scopus© Citations 3 1
Some of the metrics are blocked by your
consent settings
“Truffle sign”. A suspicious malignant pattern of lymphadenopathies in children observed on ultrasound. Preliminary study
(2023)
L. Pérez-Marrero
;
M. F. Norambuena
;
C. Whittle
;
I. M. Fuentealba
;
B. Spralja
4Scopus© Citations 4
Some of the metrics are blocked by your
consent settings
Successful treatment of cytomegalovirus retinitis with oral/intravitreal antivirals in HIV-negative patients with lymphoma
(2022)
Anastasia Tasiopoulou
;
URZUA SALINAS, CRISTHIAN
;
Susan Lightman
<jats:title>Abstract</jats:title><jats:sec> <jats:title>Objectives</jats:title> <jats:p>To report patients with systemic lymphoma and cytomegalovirus (CMV) retinitis, treated with a combination of oral and intravitreal antiviral agents on an outpatient basis.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>Retrospective cases series. Information was gathered from the database of the Uveitis clinics at Moorfields Eye Hospital, United Kingdom from December 2014 to December 2018. The inclusion criteria comprised the diagnosis of systemic lymphoma, associated with a diagnosis of CMV retinitis. Exclusion criteria were alternative ocular diagnosis, human immunodeficiency virus (HIV), primary intraocular lymphoma, or other causes of immunosuppression.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>All seven subjects had been under oncologist care for systemic lymphoma. CMV retinitis presented with a median of 61 months after the systemic lymphoma diagnosis. Five patients underwent a vitreous biopsy, and four of them returned PCR positive for CMV and the fifth patient had PCR positive in a blood sample. All patients were treated with oral Valganciclovir, with an induction dose of 900 mg every 12 h for up to 3 weeks until disease resolution and a maintenance dose thereafter. All but one received additional intravitreal Foscarnet injections, with a dose of 2.4 mg /0.1 ml.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>The management of patients with systemic lymphoma and CMV retinitis with oral and intravitreal antiviral agents, resulted in effective disease control.</jats:p> </jats:sec>
1Scopus© Citations 6
Some of the metrics are blocked by your
consent settings
Quality and capacity indicators for hospitalized pediatric oncology patients with critical illness: A modified delphi consensus
(2020)
Anita V. Arias
;
Marcela Garza
;
Srinivas Murthy
;
Adolfo Cardenas
;
Franco Diaz
5Scopus© Citations 18
Some of the metrics are blocked by your
consent settings
New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview
(2020)
Rodrigo A. Valenzuela
;
Iván Flores
;
Beatriz Urrutia
;
Francisca Fuentes
;
Pablo E. Sabat
Scopus© Citations 28 2
Some of the metrics are blocked by your
consent settings
PET/CT: Técnica, consideraciones e indicaciones en el estudio oncológico de pacientes pediátricos
(2017)
Andrés Retamal C.
;
GIANCARLO SCHIAPPACASSE FAUNDES
;
Lizbet Pérez M.
;
Pablo Alvayay Q.
;
Isabel Schild W.
6Scopus© Citations 1

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results